CRIS Current Research Information System

STEFONI, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.073
EU - Europa 5.521
AS - Asia 5.307
AF - Africa 328
SA - Sud America 298
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 17.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.989
SG - Singapore 1.600
CN - Cina 1.503
VN - Vietnam 1.129
DE - Germania 969
IT - Italia 898
GB - Regno Unito 865
NL - Olanda 817
SE - Svezia 775
HK - Hong Kong 435
RU - Federazione Russa 262
IN - India 239
BR - Brasile 222
UA - Ucraina 194
FR - Francia 188
IE - Irlanda 168
KR - Corea 150
TG - Togo 93
CI - Costa d'Avorio 83
FI - Finlandia 76
ZA - Sudafrica 74
JP - Giappone 68
JO - Giordania 61
CA - Canada 57
EE - Estonia 57
HR - Croazia 49
NG - Nigeria 40
AR - Argentina 39
PL - Polonia 39
BE - Belgio 35
CH - Svizzera 32
ID - Indonesia 30
SC - Seychelles 29
AT - Austria 25
ES - Italia 24
IR - Iran 22
MX - Messico 16
TR - Turchia 16
BG - Bulgaria 15
EC - Ecuador 11
BD - Bangladesh 9
LB - Libano 7
PE - Perù 7
CL - Cile 6
MY - Malesia 6
PY - Paraguay 6
RO - Romania 6
AU - Australia 5
IQ - Iraq 5
LT - Lituania 5
RS - Serbia 5
UZ - Uzbekistan 5
IL - Israele 4
NZ - Nuova Zelanda 4
VE - Venezuela 4
CR - Costa Rica 3
CZ - Repubblica Ceca 3
GR - Grecia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
CO - Colombia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
EU - Europa 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
KE - Kenya 1
KH - Cambogia 1
LC - Santa Lucia 1
LK - Sri Lanka 1
MK - Macedonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
OM - Oman 1
PH - Filippine 1
PW - Palau 1
TN - Tunisia 1
UY - Uruguay 1
Totale 17.541
Salva come PNG Salva come JPEG
Città #
Singapore 1.077
Southend 744
Kerkrade 666
Ashburn 660
Fairfield 624
Chandler 508
Hong Kong 429
Frankfurt am Main 377
Hefei 337
Santa Clara 333
Houston 323
Woodbridge 314
Seattle 278
Ann Arbor 269
Wilmington 256
Dong Ket 255
Cambridge 220
Beijing 210
Princeton 206
Ho Chi Minh City 173
Dublin 168
Boardman 156
Seoul 149
Bologna 145
Hanoi 117
Los Angeles 114
Milan 103
Jacksonville 100
Lomé 93
New York 91
Berlin 88
Abidjan 83
Nanjing 80
Westminster 78
Padova 68
Tokyo 64
Amman 61
Buffalo 58
Helsinki 58
Rome 55
Bremen 53
Jinan 53
Turin 52
Shenyang 44
Falkenstein 43
Abeokuta 39
San Diego 35
Kyiv 31
Saint Petersburg 31
Changsha 30
São Paulo 30
Bengaluru 29
Jiaxing 29
Munich 29
Redwood City 29
Toronto 28
Brussels 27
Florence 27
Dallas 26
Nanchang 26
Warsaw 26
Zhengzhou 26
Dearborn 24
Düsseldorf 24
Guangzhou 24
Redondo Beach 24
Des Moines 23
Hebei 22
Nuremberg 22
Bern 21
Hyderabad 21
Chicago 20
London 20
Falls Church 19
Hangzhou 19
Tianjin 19
Jakarta 18
Modena 18
Phoenix 18
Secaucus 18
Haiphong 17
Shanghai 17
Redmond 16
Taizhou 16
Yubileyny 16
Mülheim 15
Brooklyn 14
Da Nang 14
Orem 14
Taiyuan 14
Amsterdam 13
Boston 13
Olalla 13
Lappeenranta 12
Reggio Emilia 12
Sofia 12
Verona 12
Ha Long 11
Johannesburg 11
Quận Bình Thạnh 11
Totale 11.578
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 1.449
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 380
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 261
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 241
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 226
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 226
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 216
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 216
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 211
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 208
18 F-FDG PET in malignant lymphoma: significance of positive findings 208
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 207
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 205
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 202
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 196
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 195
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 195
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 190
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 189
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 187
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 184
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 183
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 182
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 181
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 179
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 175
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 172
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 171
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 170
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 170
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 169
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 168
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 165
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 164
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 163
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 163
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 162
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 155
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 155
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 152
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 152
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 152
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 151
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 150
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 148
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 148
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 146
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 146
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 146
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 145
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 145
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 145
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 144
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 144
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 144
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 143
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 143
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 143
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 142
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 139
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 138
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 138
Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. 137
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 135
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 133
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 132
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 132
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 131
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 128
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 127
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 126
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 126
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 126
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 125
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 125
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 124
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 122
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 122
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 120
Rituximab in primary conjunctiva lymphoma. 119
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 119
Corrigendum: Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient (Frontiers in Pediatrics, (2021), 9, (702546), 10.3389/fped.2021.702546) 118
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 116
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 116
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 115
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 113
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 108
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 107
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 107
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 106
Clinical significance of axillary findings in patients with lymphoma during follow up. C 106
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 101
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient 100
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy. 100
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 100
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 98
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas 94
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 93
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 93
Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma 89
Totale 16.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.666
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.666
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.131 0 0 0 0 0 131 11 81 159 61 92 596
2021/20222.113 310 54 132 258 149 98 37 133 61 145 425 311
2022/20232.366 246 346 159 300 177 185 52 140 413 68 159 121
2023/2024744 62 112 57 93 59 106 48 44 26 53 33 51
2024/20253.348 136 417 259 205 502 185 309 90 62 300 164 719
2025/20264.533 584 828 565 454 748 1.354 0 0 0 0 0 0
Totale 17.868